CompaniesOpiant Pharmaceuticals

Opiant Pharmaceuticals

defunct

About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (3)

Total Trials

3

As Lead Sponsor

3

As Collaborator

0

Total Enrollment

176

By Phase

PHASE1: 3

By Status

COMPLETED: 3

Clinical Trials Pipeline3 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2020

2021

2022

2023

Today

Hover over trial bars to see details

Recent Trials

NCT05219669Lead Sponsor

Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens

PHASE1Completed

24 participants

Started: Sep 1, 2021 · Completed: Nov 22, 2021

NCT04828005Lead Sponsor

Pharmacodynamic Evaluation of Intranasal Nalmefene

PHASE1Completed

84 participants

Started: Mar 30, 2021 · Completed: Mar 14, 2022

NCT04759768Lead Sponsor

Pharmacokinetic Evaluation of Intranasal Nalmefene

PHASE1Completed

68 participants

Started: Feb 8, 2021 · Completed: May 24, 2021

Funding History (20)

8-K

Mar 2, 2023

8-K

Mar 1, 2023

8-K

Feb 27, 2023

DEFA14A

Feb 22, 2023

DFAN14A

Feb 16, 2023

DEFA14A

Feb 7, 2023

8-K

Feb 7, 2023

DFAN14A

Feb 6, 2023

8-K

Jan 9, 2023

DEFM14A

Jan 4, 2023

Related Companies

Indivior

acquired